Fertility
Womed launches female fertility preserving device in Europe

Uterine health company, Womed, has signed licensing agreements with Kebomed Europe and Saesco Medical to distribute its first medical female fertility preserving device, Womed Leaf, in Europe.
Intrauterine Adhesions (IUA), which refer to the pathological binding of the uterine walls, are caused by scarring of the uterus after procedures such as dilation and curettage or fibroid removal, and can occur in 20 to 45 per cent of those procedures.
IUAs are a major cause of infertility, recurrent miscarriages and pain. IUA treatment is plagued with a very high recurrence rate, leaving women unsure and very anxious about their chance to conceive.
Womed Leaf is the first and only physical barrier to protect against IUA.
The device consists of a soft, flexible film made from Womed’s innovative polymer, which is inserted like an IUD at the end of a uterine procedure. It expands within the cavity, preventing contact between the uterine walls for one week, and is then naturally and painlessly discharged. Womed Leaf was proven to be highly effective in the PREG2 randomised clinical study that enrolled 160 patients with severe or moderate IUA.
“These partnerships mark the first step of a global launch that will make Womed Leaf the new gold standard in intrauterine adhesion prevention and treatment,” said Gonzague Issenmann, co-founder and CEO of Womed.
“Kebomed Europe and Saesco Medical’s established sales networks and expertise in women’s health will help European women and their doctors to preserve or recover their fertility.”
“Womed Leaf addresses a significant unmet need in women’s health and we are excited to partner with Womed to bring it to our customers,” said Lars Melbye, managing director of Kebomed Europe.
Jordi Fluvia, CEO of Saesco Medical, said: “We are committed to offering the latest advances in medical technologies, and Womed is bringing a true innovation in an indication that has been sorely lacking in meaningful improvements for the last two decades.”
Kebomed Europe will have the responsibility of selling the device in France, Germany, Sweden, Denmark, Norway, Finland, Austria and Switzerland, while Saesco Medical will cover Spain, Italy, Portugal, Belgium, the Netherlands and Luxembourg.
Fertility
Gum disease may impair female fertility and egg quality – study
Fertility
AI could transform ovarian care through personalisation, study finds

AI could transform ovarian care by personalising cancer and fertility treatment, but more clinical validation is needed before routine use.
A systematic review and meta-analysis found AI models showed high diagnostic accuracy for ovarian cancer when combining data such as ultrasound scans and blood test results.
Across 81 studies, AI models correctly identified ovarian cancer in around nine out of 10 cases, with pooled rates of 89 to 94 per cent.
They were also highly accurate at ruling out ovarian cancer when it was not present, with specificity of 85 to 91 per cent.
The analysis also found that explainable AI tools could predict complete surgical cytoreduction in advanced ovarian cancer.
Complete surgical cytoreduction means removing all visible cancer during surgery, which can be an important goal in treatment planning.
The tools achieved a pooled AUC of 0.87. AUC is a measure of how well a model distinguishes between different outcomes, with higher scores showing stronger performance.
In reproductive medicine, AI algorithms helped physicians optimise ovarian stimulation protocols and predict follicular growth during IVF.
Ovarian stimulation is the use of hormones to encourage the ovaries to produce eggs, while follicles are the small sacs in the ovaries where eggs develop.
The review found AI could reliably model ovarian response in IVF with a pooled AUC of 0.81.
However, researchers said challenges remain in translating promising research findings into routine clinical practice.
They identified substantial variation across studies, driven by retrospective study designs, variable AI systems and a lack of standardised validation.
Only 22 per cent of analysed studies reported prospective, multicentre external validation, where models are tested forward in time across multiple healthcare settings.
The authors called for rigorous validation to help close the gap between research and routine clinical practice, alongside standardised methodological and reporting frameworks, smooth integration with clinical workflow and robust governance to support responsible and ethical AI use.
They concluded: “Artificial intelligence is a transformative force in the management of ovarian conditions.
“In gynaecologic oncology, AI enhances every phase of care, from early detection and accurate diagnosis to prognostic stratification and surgical planning.”
In reproductive medicine, AI personalises ovarian stimulation and refines the diagnosis of heterogenous endocrine disorders such as PCOS.
PCOS, or polycystic ovary syndrome, is a hormonal condition that can affect periods, skin, weight and fertility.
Fertility
Housing, work and fertility stop Britons having the families they want – research
Opinion4 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
Insight3 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Menopause5 days agoPerimenopause misinformation ‘putting women at risk’
Adolescent health3 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Hormonal health3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause3 weeks agoCBT shows promise for menopause insomnia and hot flashes
Insight4 weeks agoOnline abuse and deepfakes ‘pushing women out of public life’














